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Abstract
Background Adipose tissue dysfunction contributes to obesity-
associated chronic diseases. In the first year after bariatric sur-
gery, obese patients significantly improve their metabolic status
upon losing weight. We aimed to investigate whether changes
in subcutaneous adipose tissue gene expression reflect a resto-
ration of a healthy lean phenotype after bariatric surgery.
Methods Thirty-one severely obese patients (BMI ≥ 40 kg/
m2) were examined before and after surgery. subcutaneous
adipose tissue (SAT) was collected during and 1 year after
bariatric surgery. SAT from 20 matched lean and overweight
patients (BMI < 30 kg/m2) was collected during elective ab-
dominal surgery. Baseline characteristics and SAT gene ex-
pression relevant to glucose and lipid metabolism, inflamma-
tion, and apoptosis were analyzed.
Results After surgery, mean BMI decreased from 46.1 ± 6.3 to
31.1 ± 5.7 kg/m2 and homeostasis model assessment of insulin
resistance from 5.4 ± 5.3 to 0.8 ± 0.8. SAT expression of most
analyzed inflammatory cytokines, growth factors, and metabolic
and cell surface markers was greatly downregulated even com-
pared to the lean cohort. In contrast, gene expression of TNF and
CASP3was significantly upregulated. Elastic net regression anal-
ysis showed that fasting glucose levels and CASP3 predicted
increased TNF expression in the post-obese group.
Conclusions Gene expression patterns in SAT 1 year after
bariatric surgery point to a reduced inflammation. The unex-
pected high TNF expression in SAT of post-obese subjects is
most likely not an indicator for inflammation, but rather an
indicator for increased lipolysis and adipose tissue catabolism.
Notably, after bariatric surgery SAT gene expression reflects a
cachexia-like phenotype and differs from the lean state.
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Introduction
Adipose tissue participates in whole-bodymetabolism not just
by energy storage. It is an endocrine organ and an important
site for inflammatory crosstalk and immune response.
Subcutaneous adipose tissue (SAT) is the largest adipose com-
partment for most humans and the primary site for lipid stor-
age. Excess caloric intake per se causes an activation of resi-
dent immune cells in the adipose tissue, to which other im-
mune cells are attracted from the circulation [1]. Long-term
overnutrition leads to a chronic low-grade inflammation,
which promotes insulin resistance, for instance via insulin
receptor substrate 2 (IRS2) downregulation in SAT [2] and
thus precedes type 2 diabetes mellitus (T2DM) and other met-
abolic disorders [3]. In the development of chronic inflamma-
tion, T cells induce the infiltration and inflammatory
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polarization of macrophages in the adipose tissue [4, 5], which
can make up to 40 % of cell content in obesity. These inflam-
matory macrophages have higher lipid content in murine
models of obesity and show increased expression of genes
relevant to lipid metabolism, such as peroxisome proliferator
nuclear receptor gamma (PPARG) [6]. Additionally, immune
cells are the major source of several inflammatory cytokines
such as the cachexia-inducing tumor necrosis factor (TNF)-α,
interleukin 6 (IL6), and interleukin 1β (IL1B) [12]. Notably,
insulin resistance and lipolysis are both mediated by TNF.
Lipolysis is enhanced by TNF through downregulating of
perilipin 1 (PLIN1), which protects adipocytes from lipolysis
by modulating substrate availability for hormone-sensitive li-
pase [7], and cell death-inducing DNA fragmentation factor-
alpha-like effector A (CIDEA) expression, which is enriched
at lipid droplet contact sites [8, 9]. SAT Expression of both
PLIN1 and CIDEA correlates with insulin sensitivity in obe-
sity [9]. Moreover, adipose tissue of obese compared to lean
subjects secretes reduced concentrations of the insulin-
sensitizing adipokine adiponectin (ADIPOQ) [10]. Overall,
these cytokines and adipokines play a crucial role in the de-
velopment of adipose tissue inflammation and insulin resis-
tance [11–13].
Weight loss is key to restoring insulin sensitivity and re-
ducing cardiovascular risk. Currently, bariatric surgery is the
most sustainable treatment option, superior to lifestyle inter-
ventions in terms of weight maintenance and risk reduction
[14]. Long-term remission of T2DM in obese patients under-
going bariatric surgery has been frequently reported: 1 year
after surgery, the hemoglobin A1c level improved significant-
ly, and disease-related mortality was reduced compared to
conservative therapy [15, 16]. On the other hand, weight loss
following bariatric surgery resembles in some cases of cachex-
ia [17]. Although cachexia and obesity are on opposite sides
of the weight spectrum, they display many similarities as both
are characterized by increased adipose tissue lipolysis and
insulin resistance.
Growth factors, which are important for adipogenesis, are
downregulated in catabolic states and cachexia, which are
characterized by low levels of insulin growth factor 1 (IGF-
1) and increased levels of transforming growth factor beta
(TGF-β) family members [18]. Myostatin is a member of
the TGF-β family and a negative regulator of muscle growth;
however, it is not clear how weight loss after bariatric surgery
affects serum myostatin levels.
Changes in adipose tissue gene expression during
weight loss after bariatric surgery treatment of morbid
obesity are to date underinvestigated. We set out to inves-
tigate the effects of weight loss on genes relevant to in-
flammation, lipolysis, apoptosis, and growth in adipose
tissue 1 year after surgery and to compare expression




The trial has been performed in accordance to the 1964
Declaration of Helsinki and its latter amendments and with
the Good Clinical Practice guidelines at the Department of
Medicine III, Medical University of Vienna. All participants
provided informed written consent prior to their inclusion in
the study. The trial had been approved by the Ethics
Committee of the Medical University of Vienna (EK-Nr.
488/2006, EK 275/2006, and EK-Nr. 963/2009) and by the
Ethics Committee of the Göttlicher Heiland Hospital (EK-Nr.
E10-N01-01) and was conducted at the Clinical Research Unit
of the Division of Endocrinology and Metabolism,
Department of Medicine III, Medical University of Vienna.
Study Population
Morbidly obese patients (BMI > 40 kg/m2) prior to and 1 year
after bariatric surgery were compared to a group of lean and
overweight patients. We investigated metabolic parameters
and SAT gene expression of 31 morbidly obese patients
(BMI > 40 kg/m2) before and approximately 1 year after elec-
tive bariatric surgery (follow-up time 419 ± 58 days). Adipose
tissue and serum samples were collected within another study
from n = 20 lean and overweight donors (BMI < 30 kg/m2)
undergoing elective abdominal surgery either at the
Department of Surgery from the Medical University of
Vienna or the Hospital Göttlicher Heiland in Vienna. Results
have been published elsewhere [19, 20]. For comparison of
gene expression, a subgroup of n = 20 obese patients matched
for age and sex with the lean and overweight were analyzed.
Obese patients were advised to maintain usual physical
activity at a constant level. No intensive exercise routines were
documented. All obese patients participated in previous trials
by our group and metabolic changes 1 year after bariatric
surgery have been presented elsewhere [21]. Briefly, 20–65-
year-old patients scheduled to undergo bariatric surgery or
elective abdominal surgery were eligible for inclusion if their
BMI was >40 kg/m2 before surgery for the obese group and
<30 kg/m2 for the lean and overweight control group, and
their fasting plasma glucose <126 mg/dl and 2-h plasma glu-
cose after a 75-g oral-glucose tolerance test <200 mg/dl.
Exclusion criteria included acute illness within the past
14 days or severe chronic illness such as active malignancies;
acquired immunodeficiency (HIV infection, AIDS); signifi-
cant liver, cardiovascular, renal, pulmonary or thyroid disease;
anemia; inborn or acquired bleeding disorders; as well as
pregnancy or breastfeeding. Anthropometric parameters were
determined at inclusion and at the 1-year follow-up visit after
bariatric surgery. All patients were Caucasian.
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Collection of Subcutaneous Adipose Tissue
All bariatric surgeries (26 Roux-en-Y-gastric bypass (RYGB),
three sleeve resections, and two gastric bandings) had been
performed at the Department of Surgery of the Medical
University of Vienna. Samples of SAT were collected by ex-
cision from the umbilical area during surgery. Other elective
abdominal surgeries had been performed at the Department of
Surgery of the Medical University of Vienna and the
Göttlicher Heiland Hospital, Vienna. SAT was collected by
excision from the periumbilical region. One year after bariatric
surgery, the post-obese SATwas collected by needle biopsy of
the periumbilical abdominal area. All adipose tissue samples
were immediately immersed in RNAlater (Life Technologies)
and stored at −80 °C.
Serum Samples and Laboratory Analysis
Blood samples were collected by venous puncture after a 12-h
overnight fast. Blood samples were analyzed by the
Department of Laboratory Medicine, Medical University of
Vienna, for routine analysis of triglycerides, total-, HDL-
and LDL-cholesterol, alanine transaminase (ALT), gamma-
glutamyl transferase (GGT), glucose, insulin, C-peptide, C-
reactive protein (CRP), glycosylated hemoglobin (HbA1c),
and red and white blood cell counts. For ELISA analyses,
blood was centrifuged at 3000g for 10 min at 4 °C and then
stored at −20 °C. We used commercial ELISA kits to measure
plasma concentrations of IL-6 (R&D Systems, Minneapolis,
MN, USA) and serum concentrations of high-sensitivity tu-
mor necrosis factor (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) and myostatin (R&D Systems,
Minneapolis, MN, USA) and a RIA for measuring serum
adiponectin concentrations (Merck Millipore, Billerica, MA,
USA). Homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated as the product of fasting insulin
(μU/ml) and glucose (mg/dl) divided by 405.
Adipose Tissue RNA Extraction and Gene Expression
Analysis
Total RNA from tissue was extracted by using the RNeasy
Lipid Tissue Mini Kit (QIAGEN, Venlo, Netherlands) and
by TRIzol reagent (Thermo Fisher Scientific, Waltham, MA,
USA) with a tissue homogenizer, followed by RNA isolation
according the manufacturer’s instructions. RT-PCR was per-
formed in duplicates by using the TaqMan Gene Expression
Assays (Applied Biosystems). Gene expression was analyzed
according to the ddCt method relating gene of interest Ct
values to ubiquitin C (UBC). No significant differences in
the Ct values of UBC were observed between the groups. To
ensure that SAT biopsies are not contaminated with dermis
tissue, keratin 18 (KRT18) expression was analyzed and three
positive post-obese samples (gene expression >1000 % post-
obese sample in comparison to the obese sample of the same
patient) were excluded. A list of used TaqMan probes is pro-
vided in the supplementary Table 1.
Statistical Analysis
Normal distribution was determined by the Shapiro-Wilk test
of normality. Normally distributed data were presented as
means ± SDs, otherwise as medians (interquartile ranges).
Group differences were calculated by one-way ANOVAwith
Tukey post hoc test or Kruskal-Wallis rank sum with Dunn’s
multiple comparison test, and paired t test, orWilcoxon signed
rank test for paired samples, as appropriate.
For gene expression comparison ddCt-data were investi-
gated independently by linear mixed effects analysis of gene
expression, with the fixed effects status (lean, obese, or post-
obese) and plate (obese before and after bariatric surgery or
lean and obese) and the patient ID as a random effect. No
apparent deviations from homoscedasticity or normality were
observed in the residual plot. Relative gene expression
boxplots were normalized to the median of the obese group.
Data were not adjusted for multiple testing due to the study’s
exploratory nature. For Pearson’s r correlation, nonparametric
data were log-transformed. For the elastic net equation, the
optimal settings for α (between 0 and 1) and for λ plus one
standard error [22] were chosen to minimize the mean squared
error using leave-one-out cross-validation. To investigate the
relationship of TNFwith other genes, we correlated its expres-
sion with assessed parameters in the post-obese group and
performed an unbiased machine learning analysis via elastic
net regularization, to check for independent predictors.
For statistical analysis, we used RStudio (version 0.99.491)
[23] with R (version 3.2.2) [24] with the lme4 (1.1–10) [25]
and the glmnet (2.0–2) packages [26]. Differences were con-
sidered statistically significant at two-sided values of p < 0.05.
Results
Changes in AnthropometricMeasurements andMetabolic
Parameters after Bariatric Surgery
Obese patients were matched to lean patients according to age
and sex. Anthropometric measurements and metabolic param-
eters of the obese group at baseline and 1 year after bariatric
surgery (post-obese) compared to the lean group are reported
in Table 1. Post-obese patients significantly lost weight (mean
ΔBMI 15 kg/m2) and showed improvedmetabolic parameters
such as serum lipids (triglycerides, total cholesterol LDL-C);
liver tests (ALT, GGT); and CRP concentration. Changes in
glucose metabolism including insulin sensitivity and pancre-
atic β cell function, assessed by HOMA-IR and other OGTT-
OBES SURG
derived indices were extensive and have already been present-
ed elsewhere [21].
Myostatin serum levels were significantly increased in
obese subjects compared to lean but normalized after weight
loss (Table 1). After surgery plasma IL-6 and TNF concentra-
tions decreased significantly, whereas adiponectin concentra-
tion increased. Although the BMI of the post-obese group was
higher compared to the lean group, some metabolic parame-
ters including plasma triglycerides, fasting glucose, insulin,
and HOMA-IR were significantly lower (Table 1).
SAT Expression of Inflammatory Cytokines
Differences in SAT gene expression in the obese, post-obese,
and lean group were analyzed by linear mixed effects model.
In comparison, most inflammatory genes (IL1B, IL6, CCL3)
in the post-obese group were dramatically downregulated.
Notably, the cachexia-associated, pro-inflammatory TNF
was upregulated 2.9-fold after weight loss, while expression
of all interleukins (IL1B, IL6, IL10), as well as CCL3 was
much lower than in the lean group (Fig. 1).
SAT Expression of Relevant Metabolic Genes
Since inflammatory gene expression, except TNF, was greatly
reduced after surgery, we investigated the impact of weight
loss on relevant metabolic genes. Compared only with the lean
group, SATADIPOQ expression of obese patients before sur-
gery was in trend lower (p = 0.07). In the post-obese group,
ADIPOQ expression was significantly downregulated after
Table 1 Characteristics of lean,
obese, and post-obese patients Lean (n = 20) Obese (n = 31) Post-obese (n = 31) p value
Sex (f/m) 15/5 24/7 24/7
Age (years) 43 ± 9 42 ± 12 43 ± 12 0.89
Anthropometric measurements
BMI (kg/m2) 25.5 ± 3.1* 46.1 ± 6.3† 31.1 ± 5.7‡ <0.01
WHR 0.90 (0.84–0.94) 0.91 (0.87–0.95) 0.88 (0.85–0.92) 0.22
Metabolic parameters
Triglycerides (mg/dl) 125.0 (95.0–180.5) 138.0 (120.5–193.5)† 94.0 (71.5–116.5)‡ <0.01
Total cholesterol (mg/dl) 181.5 ± 34.9* 205.0 ± 33.0† 165.5 ± 32.3 <0.01
HDL-C (mg/dl) 38.0 (35.3–41.8)* 45.0 (41.0–53.0)† 51.0 (45.5–55.5)‡ <0.01
LDL-C (mg/dl) 116.3 (90.7–124.1)* 134.0 (102.5–140.0)† 90.8 (81.4–104.1)‡ <0.01
ALT (U/l) 14.0 (10.5–24.5)* 27.0 (21.0–35.5)† 19.5 (15.3–24.8)‡ <0.01
GGT (U/l) 23.0 (16.0–38.0)* 39.0 (22.0–50.0)† 16.0 (11.0–27.0)# <0.01
Fasting glucose (mg/dl) 95.6 ± 15.9 94.4 ± 9.8† 77.8 ± 8.1‡ <0.01
Insulin (μU/ml) 8.0 (2.5–15.6)* 17.1 (6.2–30.8)† 2.0 (2.0–4.0)‡ <0.01
C-peptide (ng/ml) 0.5 (0.1–0.8)* 3.9 (2.9–4.7)† 1.9 (1.4–2.3)‡ <0.01
HOMA-IR 2.0 (0.5–3.2)* 4.0 (1.4–7.8)† 0.4 (0.4–0.9)‡ <0.01
CRP (mg/dl) 0.10 (0.08–0.23)* 0.89 (0.36–1.16)† 0.2 (0.1–0.3) <0.01
Myostatin (ng/ml) 2.7 (2.1–3.4)* 3.8 (2.5–4.5)† 2.9 (2.3–3.6) 0.03
HbA1c (%) 5.5 ± 0.4 5.3 ± 0.3 <0.01
IL-6 (pg/ml) 3.2 (2.3–4.6) 1.4 (1.0–1.7) <0.01
Adiponectin (μg/ml) 7.4 ± 2.8 11.2 ± 5.0 <0.01
TNF (pg/ml) 2.7 ± 0.9 1.8 ± 0.6 <0.01
IGF1 (ng/ml) 108.0 (95.0–125.5) 127.0 (85.8–188.3) 0.06
Albumin (mg/dl) 41.7 ± 2.4 41.2 ± 2.8 0.22
Values are depicted as mean ± SD or median (IQR). Statistical significance was calculated by one-way ANOVA
with Tukey post hoc test or Kruskal-Wallis rank sum with Dunn’s multiple comparison test as appropriate and for
HbA1c, IL-6, adiponectin, and TNF by paired t test or Wilcoxon signed rank test for paired samples
ALT alanine transaminase, CRP C-reactive protein, GGT gamma-glutamyl-transferase, HbA1c hemoglobin A1c,
HDL-C high-density lipoprotein cholesterol,HOMA-IR homeostatic model assessment–insulin resistance, LDL-C
low-density lipoprotein cholesterol, WHR waist to hip ratio
*Lean vs obese = p < 0.05
†Obese vs post-obese = p < 0.05
‡Lean vs post-obese = p < 0.05
# Lean vs post-obese = p = 0.52
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weight loss. We detected a similar expression pattern between
the SAT expression of metabolism-relevant genes such as
IRS2, PPARG, and SLC2A4: while lean and obese group did
not differ, messenger RNA (mRNA) expressions of the post-
obese group compared to the lean and the obese groups were
dramatically reduced (p < 0.01, Fig. 2). SAT expression of
regulators of lipid turnover showed that mRNA expression
of the antilipolytic lipid droplet proteins PLIN1 and CIDEA
are significantly downregulated in the post-obese group. In
contrast, the apoptosis effector gene caspase-3 (CASP3) is
upregulated in obese and even further upregulated in post-
obese patients (Fig. 2).
SAT Expression of Cell Surface Molecules
Since the expression ofCASP3was upregulated in response to
weight loss, we investigated whether the expression of cell
surface marker would reflect the catabolic processes induced
by apoptosis. The M1 macrophage marker CD40 did not dif-
fer in mRNA expression between the groups and seemed un-
affected by weight loss. In contrast, SAT expression of
markers for macrophages (CD68), Tcells (CD3E), endothelial
cells (CD144), and antigen-presenting cells (HLA-DR) de-
creased significantly compared to their expression before sur-
gery. Of note, in the post-obese group SATexpression of Tcell
marker CD3E and of macrophage marker CD68 was even
more reduced compared to the lean group (Fig. 3).
SAT Expression of Growth Factors
We next analyzed the SAT expression of growth factors rele-
vant to obesity. The fibroblast growth factor 1 (FGF1), insulin
growth factor 1 (IGF-1), and angiogenic vascular endothelial
growth factor C (VEGFC) were downregulated after bariatric
intervention (Fig. 4). Expression of FGF1 and IGF1was even
below the values of the lean group.
Correlation Analysis of TNF Gene Expression
after Bariatric Surgery
One of the most noteworthy findings in the post-obese group
was that TNF expression was markedly upregulated upon
weight loss (Fig. 1). Therefore, we investigated factors mod-
ulating TNF expression in serum or on gene expression level.
By calculating Pearson’s correlation coefficient, we observed
a positive correlation between TNF expression, fasting blood
glucose, and CASP3 expression and a negative correlation
with IGF1, PLIN1, PPARG, and SLC2A4 expression
(Table 2). To identify independent predictors of TNF expres-
sion, we performed a linear regression analysis with an elastic
net regularization, in which all parameters were included. The
analysis showed that fasting glucose levels (mg/dl), CASP3,
and CD40 increase, whereas SLC2A4 decreases TNF expres-
sion in the post-obese group.
Discussion
Our present work aimed to investigate SAT expression of rel-
evant inflammatory and metabolic genes of morbidly obese
patients before and 1 year after bariatric surgery in comparison
to lean subjects. Even though the mean BMI of patients in the
post-obese group was still higher compared to the lean control
group, most metabolic risk factors, such as insulin resistance,
hyperlipidemia, and systemic inflammation, changed to such
an extent that many of the analyzed parameters in serum dif-
fered even from the lean control group. Interestingly, analysis
of adipose tissue inflammation-associated genes showed that
gene expression profile of the post-obese group was signifi-
cantly different in comparison to the obese and even the lean
control group and pointed to reduced inflammation. We fur-
ther showed that weight loss affected several genes relevant to
lipolysis, apoptosis, and also growth factors with a role in
cachexia. Accordingly, it seems that the near to normal weight
achieved after bariatric surgery reflects a cachexia-like state
rather than a healthy lean phenotype, particularly indicated by
the extensive upregulation of TNF expression in the post-
obese group.
Macrophage-associated inflammatory cytokines like IL1B,
IL6, and CCL3 were all upregulated in obese SAT [27–29],
but markedly downregulated after bariatric surgery, concor-
dant with other data [30, 31]. Interestingly, the anti-
inflammatory IL10 was downregulated upon weight loss.
The finding that TNF was markedly upregulated contrasts

































Fig. 1 SAT expression of inflammatory cytokines. Boxplots of IL1B,
IL6, CCL3, TNF, and IL10 expression in SAT of lean (white), obese
(hatched), and post-obese (gray) subjects are presented. Comparisons
were made between lean-obese, obese-post-obese, and post-obese-lean
subjects by Tukey’s Test. *p < 0.05; **p < 0.01; ***p < 0.001
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response to weight loss was lower, the follow-up time was
shorter, or the cohorts included diabetic-patients [30, 32].
TNF was originally described as the cachexia-inducing
factor and termed cachectin indicating a Janus-type function
[33]. It is known to mediate lipolysis and insulin resistance by
downregulation of PLIN1 [7] andCIDEA expression [8]. TNF
was described to cause apoptosis of adipocytes in vitro in a
CASP3-dependent manner [34]. Notably, CASP3 expression
is higher in SAT in obesity in our study as well as in other
studies [35]. Since the number of adipocytes in adults is de-
scribed to be unchanged upon weight gain or weight loss [36],
CASP3 upregulation might be explained by increased apopto-
sis of inflammatory immune cells from the stromal vascular
fraction [37], as evidenced by the remarkable decrease in T
cell marker CD3E, pan-macrophage marker CD68, endothe-
lial cell marker CD144 and antigen-presenting cell marker
HLA-DR. In our post-obese group, CASP3 expression in adi-
pose tissue is even higher than in the obese group, clearly
indicating a catabolic state.
TNF inhibits adipogenesis by downregulating PPARG ex-
pression in cultured human adipocytes [38]. We detected in-
creased lipolysis and reduced adipogenesis in our cohort. The
downregulation of metabolic markers ADIPOQ, IRS2,
PPARG, and SCL2A4 (GLUT-4) expression after weight loss
indicates reduced metabolism in adipose tissue. A study per-








































Fig. 2 SAT expression of
relevant metabolic genes.
Boxplots of ADIPOQ, IRS2,
PPARG, SCL2A4, PLIN1,
CIDEA, andCASP3 expression in
SAT of lean (white), obese
(hatched), and post-obese (gray)
subjects are presented.
Comparisons were made between
lean-obese, obese-post-obese, and
post-obese-lean subjects by
Tukey’s test. *p < 0.05;































Fig. 3 SAT expression of cell surface molecules. Boxplots of CD40,
CD68, CD3E, CD144, and HLA-DR expression in SAT of lean (white),
obese (hatched), and post-obese (gray) subjects are presented.
Comparisons were made between lean-obese, obese-post-obese, and































Fig. 4 SAT expression of growth factors. Boxplots of FGF1, IGF1,
VEGFC expression in SAT of lean (white), obese (hatched), and post-
obese (gray) subjects are presented. Comparisons were made between
lean-obese, obese-post-obese, and post-obese-lean subjects by Tukey’s
test. *p < 0.05; **p < 0.01; ***p < 0.001
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PPARG downregulation suggests an inhibition of adipogene-
sis and concomitant insulin resistance in SAT during weight
loss [40]. Other studies also showed a decrease in PPARG
after hypocaloric diet or 3 months after bariatric surgery
[41–43]. Other adipogenesis-related genes such as IGF1 [44]
and FGF1 were also significantly downregulated in the post-
obese group. The preadipocyte differentiation marker FGF1
was downregulated in post-obese SAT, contrary to the find-
ings of Mejhert et al. who did not detect any differences in
FGF1 secretion after 10 weeks of diet-induced weight loss
[45]. However, the weight loss was, notably, not as pro-
nounced as we observed 1 year after bariatric surgery.
Although insulin pathway genes were downregulated,
whole-body insulin sensitivity was restored in the post-
obese group as suggested by the HOMA-IR and as noted
previously [21]. Surprisingly, TNF expression in post-
obese could be predicted by fasting glucose, although
fasting glucose values were already lower in comparison
to the lean control group. Interestingly, TNF expression in
SAT after bariatric surgery is independent of whole-body
insulin resistance, contrary to the obese state. Local insulin
resistance seems to occur in SAT, similar to cachectic
states. In contrast to a previous study [46], the pro-
inflammatory M1 macrophage marker CD40 was not
Table 2 Correlations and elastic
net regression for TNF gene
expression in post-obese SAT
r p value r p value
Age (years) 0.02 0.93 Gene expression
BMI (kg/m2) 0.01 0.95 ADIPOQ −0.38 0.06
WHR 0.02 0.94 CASP3 0.56 <0.01
CCL3 −0.34 0.18
Serum parameters CD144 −0.29 0.14
Triglycerides (mg/dl) 0.20 0.33 CD3E 0.30 0.13
Total cholesterol (mg/dl) −0.23 0.25 CD40 0.34 0.09
HDL-C (mg/dl) −0.26 0.20 CD68 −0.29 0.15
LDL-C (mg/dl) −0.25 0.21 CIDEA -0.37 0.06
ALT (U/l) 0.23 0.21 FGF1 −0.33 0.10
GGT (U/l) 0.31 0.13 HLA-DR 0.10 0.63
Glucose (mg/dl) 0.39 0.04 IGF1 −0.43 0.03
Insulin (μU/ml) 0.00 0.98 IL10 −0.18 0.40
C-peptide (ng/ml) −0.03 0.87 IL1B −0.17 0.42
HOMA-IR 0.02 0.91 IL6 −0.33 0.13
CRP (mg/dl) 0.12 0.56 IRS2 −0.15 0.47
HbA1c (%) −0.03 0.90 PLIN1 −0.44 0.03
Myostatin (ng/ml) 0.22 0.37 PPARG −0.48 0.01
IL-6 (pg/ml) 0.26 0.20 SLC2A4 −0.54 <0.01
Adiponectin (μg/ml) 0.03 0.90 VEGFC −0.27 0.18
TNF (pg/ml) 0.07 0.72
IGF1 (ng/ml) −0.25 0.20
Albumin (mg/dl) 0.24 0.21





Significant correlations are highlighted in italics.B coefficients represent the unstandardized regression coefficient
of the independent variables, which describe the ddCt values of TNF via elastic net regression. Elastic net
parameters were chosen to minimize the mean squared error of the linear regression as following: the relative
strength of the L1 and L2 penalty term α = 0.86 and the regression penalty λ = 0.30. The intercept of the
regression was 0.950
r Pearson correlation coefficient, p significance level, ALT alanine transaminase, CRP C-reactive protein, GGT
gamma-glutamyl-transferase, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, HOMA-IR
homeostatic model assessment–insulin resistance, LDL-C low-density lipoprotein cholesterol, WHR waist to hip
ratio, a.u. arbitrary units
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reduced in the post-obese group, although the pan-
macrophage marker CD68 expression was downregulated.
The increased CD40/CD68 ratio together with the down-
regulation of PPARG and ADIPOQ suggest a shift towards
local insulin resistance inducing M1-like macrophages in
SAT [47–50]. M1 macrophages are the primary source of
TNF and seem to orchestrate insulin resistance [51].
Interestingly, although the expression of the immune cell
marker CD40 does not change significantly, elastic net re-
vealed TNF expression acts as a positive predictor.
Therefore, CD40-positive cells could be a source of the
TNF upregulation in the SAT of post-obese patients. Of
note, an increased apoptosis rate may also cause TNF up-
regulation by the so-called apoptosis-induced apoptosis,
where dying cells secrete TNF, which then in turn induce
even more apoptosis [52]. A proposed mechanism for TNF
modulation of lipolysis in adipose tissue after weight loss
is described in Fig. 5.
Weight loss after bariatric surgery can sometimes lead to
a pronounced reduction of fat and fat-free mass similar to
cachexia [17]. Muscle wasting is relevant to cachexia;
however, whole body muscle mass changes were not ana-
lyzed. Since myostatin (MSTN) levels correlate negatively
with muscle mass and high circulating levels of MSTN
were observed in muscle wasting conditions [53, 54],
MSTN was used as surrogate marker of skeletal muscle
mass. To our knowledge, we are the first to report changes
in myostatin serum concentration after weight loss induced
by bariatric surgery. Consistent with the findings of Park
et al. in muscle biopsies of obese subjects ~1 year after
bariatric surgery, we observed a significant decrease in
circulating myostatin levels upon weight loss, which ap-
proximated the level of the lean group [55], suggesting that
muscle wasting is not too advanced.
Regarding other growth factors related to both obesity and
cachexia, our group showed that serum IGF-1 concentration
increases in trend after surgery and is associated with a risk for
developing post-load hypoglycemia 2 h after a standardized
glucose challenge [21]. Downregulated IGF1 in SAT in the
post-obese group indicates that IGF-1-concentration is
uncoupled from SATexpression, since serum IGF-1 is primar-
ily hepatic [56].
Other examples of uncoupled SAT expression-serum
concentration include circulating adiponectin and TNF.
The increase in adiponectin concentration in serum 1 year
after surgery did not reflect an increase in SAT ADIPOQ
expression, although SAT is believed to be the main source
of serum adiponectin [57], suggesting that in the post-
obese, other fat depots, most likely bone marrow adipose
tissue, significantly contributes to adiponectin serum levels
[58]. Also, others observed that circulating adiponectin in-
creases, while IL-6 and TNF concentration decreases upon
weight loss [59, 60]. However, SAT IL6 expression is
described to be connected with serum levels in humans
while TNF expression is not—meaning that TNF primarily
acts in a paracrine or autocrine manner [61].
A limitation to our study is that the data merely present a
Bsnapshot^ during weight loss, as we did not include mul-
tiple time points after bariatric surgery. It would be inter-
esting to know whether expression profiles after 5 or
10 years will resemble a healthy lean state in contrast to
the catabolic state we observed in our study. An additional
limitation of this study is that due to obvious reasons, we
could only collect subcutaneous and not omental adipose
tissue during follow-up. The amount of collected tissue by
needle biopsy was very limited. Therefore, only mRNA
expression could be investigated but neither histology nor
protein expression. Adipose tissue samples were collected
by excision during surgery for the lean and obese group
and by needle biopsy in the pos t -obese group.
Contradictory data are published on whether adipose tissue
sampling affects gene expression analysis [77,78], yet we
did not observe any significant differences between surgi-
cal excision and needle biopsy either (data not shown). For
an inclusive statistical analysis, we performed a linear
mixed effects model, taking into account the fact that due
to sample size, considerations loss of power in comparing
the lean with the obese group would occur.
Most studies focusing on bariatric surgery follow-up
mainly investigated changes in serum parameters, whereas
only few investigated changes in the expression of adipose
tissue inflammation and cachexia-related genes. A major
strength of our study is the thorough characterization of
systemic and local adipose tissue changes after weight loss
and the comparison to the lean state, as well as the novel
finding that upon bariatric surgery, a state similar to ca-
chexia seems to develop in SAT. Similarities and differ-
ences between post-bariatric weight loss as evaluated in
this study and published data on cachexia [17, 62, 63] are
presented in supplementary Table 2.
In summary, our data suggest that in response to
surgery-induced weight loss, upregulated TNF expression
leads to increased lipolysis via PLIN1 downregulation, de-
creased adipogenesis via PPARG downregulation and even
increased adipocyte turnover via CASP3 upregulation.
Concomitant with lipolysis, local insulin resistance also
occurs in cachexia and was reflected in our study by the
downregulation of PLIN1, CIDEA, SLC2A4, ADIPOQ,
IRS2, and PPARG. Thus, the profound weight loss caused
a specific pattern in SAT gene expression, which let us
conclude that the post-obese SAT reflects a cachexia-like
state rather than healthiness. For a more in-depth analysis
of the biological processes occurring in different human fat
depots during weight loss, the mechanisms through which
these changes contribute to whole-body metabolism need
to be investigated in further studies.
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